Laboratory Corporation of America Holdings(LH)

New York Stock Exchange
Sector: Healthcare | Industry: Medical - Equipment & Services
Laboratory Corporation of America Holdings logo

Laboratory Corporation of America Holdings operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; and online applications for managed care organizations and accountable care organizations. It offers end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves managed care organizations, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories. Laboratory Corporation of America Holdings has a collaboration agreement with Tigerlily Foundation to increase clinical trial diversity for women of color. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.

Latest News & Analysis

Labcorp's strategic growth in self-testing, Alzheimer's diagnostics, and oncology, impacting market share and investor confidence.
Apr 9, 2025

Labcorp (LH): Self-Testing, Alzheimer's & Oncology Expansion

Labcorp (LH) expands diagnostics with self-testing, Alzheimer's advancements, and BioReference Health's oncology assets, aiming to boost revenue and investor confidence.

Read more →
Labcorp acquires BioReference Health oncology assets: strategic financial move impacting revenue, market share, and diagnostic innovation. Stay informed.
Mar 19, 2025

Labcorp's Oncology Expansion: Analyzing the BioReference Acquisition

Labcorp's acquisition of BioReference Health's oncology assets: financial implications, market impact, and future growth prospects analyzed.

Read more →
Labcorp expands oncology diagnostics with BioReference Health acquisition. Analysis of financial performance, market competition, and strategic growth.
Mar 14, 2025

Labcorp's Oncology Expansion: Analyzing the BioReference Deal

Labcorp's strategic acquisition of BioReference Health's oncology assets aims to expand its presence in the oncology diagnostics market.

Read more →
Labcorp's strategic moves in oncology: acquisitions, liquid biopsy advancements, and financial outlook. A comprehensive analysis for investors.
Mar 11, 2025

Labcorp (LH): Strategic Acquisitions, Liquid Biopsy, and the Future of Diagnostics

Labcorp (LH) is strategically expanding its oncology services through acquisitions like BioReference Health and innovative diagnostics like Plasma Complete. Financial health is solid.

Read more →
Labcorp's liquid biopsy: Revolutionizing cancer diagnostics with non-invasive blood tests. Stay informed on LH stock, acquisitions, and future growth in the diagnostics market.
Mar 6, 2025

Labcorp (LH): Liquid Biopsy, Acquisitions, and Growth Analysis

Analysis of Labcorp's (LH) strategic moves, liquid biopsy test, and competitive landscape. Financial insights and growth opportunities for investors.

Read more →
Labcorp Financial Analysis: Revenue Growth, Liquid Biopsy Innovation, and Strategic Outlook for 2025 in Healthcare Diagnostics.
Feb 28, 2025

Labcorp (LH) Strategic Outlook: Liquid Biopsy, Fortrea Spin-off, and 2025 Growth Analysis

Labcorp (LH) is strategically navigating healthcare innovation with liquid biopsy, Fortrea spin-off, and strong 2025 growth projections. This analysis explores the key developments and insights.

Read more →
Labcorp Q4 2024 earnings analysis: Revenue growth, strategic initiatives, and market outlook.
Feb 27, 2025

Labcorp (LH): Q4 2024 Earnings, Strategic Initiatives

Labcorp's Q4 2024 results beat expectations, driven by strategic initiatives and growth in key markets. Investors should monitor Invitae integration and reimbursement landscape.

Read more →
Labcorp Q4 2024 Performance: Financial analysis, strategic initiatives, and future outlook for LH stock.
Feb 26, 2025

Labcorp (LH): Q4 2024 Performance, Strategic Initiatives

Labcorp (LH) reported strong Q4 2024 results, exceeding expectations. Strategic moves and innovative tests position it for growth, though margin compression is a concern.

Read more →
Labcorp Q4 2024 Earnings: Analysis of revenue, EPS, strategic growth initiatives, and market outlook for investors.
Feb 25, 2025

Labcorp (LH) Q4 2024 Earnings: Strategic Growth and Market Outlook

Labcorp's Q4 2024 earnings showcase strategic growth and a positive market outlook, driven by innovative diagnostics and strategic initiatives.

Read more →
Labcorp Q4 2024 Earnings Analysis: Liquid Biopsy Advancements and Strategic Outlook for Investors
Feb 24, 2025

Labcorp (LH): Q4 Earnings, Liquid Biopsy, and Strategic Outlook

Labcorp's Q4 earnings beat expectations, driven by strategic initiatives and liquid biopsy advancements. Margin pressures persist, but growth prospects remain strong.

Read more →
Labcorp Q4 2024 Performance Analysis: Revenue Growth, EPS, and Strategic Initiatives. Financial outlook and market analysis.
Feb 21, 2025

Labcorp Q4 2024 Earnings: Strategic Initiatives & Market Impact

Labcorp exceeded Q4 2024 earnings expectations with robust revenue growth amid margin compression and strategic initiatives driving future market impact.

Read more →
LabCorp strategic analysis: Q4 earnings, market dynamics, and LH stock performance.
Feb 21, 2025

LabCorp Announces Major Business Developments

LabCorp's Q4 2024 earnings beat forecasts, but margin concerns linger. Strategic initiatives and market dynamics shape its path forward. Read the latest analysis.

Read more →
LabCorp (LH) stock analysis: Q4 earnings, strategic initiatives, and market dynamics impacting LH investment decisions. Stay informed on LabCorp's financial performance and outlook.
Feb 20, 2025

LabCorp Announces Major Business Developments | Latest Industry News

LabCorp (LH) navigates strategic initiatives, Q4 earnings beat, and market dynamics amid analyst optimism and margin concerns.

Read more →
Laboratory equipment on a clean bench.
Feb 18, 2025

Labcorp Core Strengths and Strategic Acquisitions Fuel Growth

Explore Labcorp's strong Q4 2024 earnings, strategic acquisitions including Invitae, and innovative initiatives that fuel growth and address market challenges.

Read more →